New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate.

A very good review of inhibitors to coagulation factors, in congenital or acquired hemophilia, that covers the incidence, pathogenesis, treatment strategies (including different alternatives to human factors), and induction of immune tolerance. The article contains an algorithm approach for the management of such patients, with emphasis on the use of rFVIIa in managing hemophiliac patients with inhibitors, covering the advantages and disadvantages of this treatment. It highlights the efficacy and safety of this treatment.

– M. Aldouri.